Goldman Sachs Group Inc Fulcrum Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 542,258 shares of FULC stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
542,258
Previous 927,961 41.56%
Holding current value
$2.09 Million
Previous $3.31 Million 23.07%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
SELL
$2.97 - $4.84 $1.15 Million - $1.87 Million
-385,703 Reduced 41.56%
542,258 $2.55 Million
Q3 2024

Nov 14, 2024
BUY
$3.18 - $9.74 $1.17 Million - $3.58 Million
367,469 Added 65.56%
927,961 $3.31 Million
Q2 2024

Aug 13, 2024
SELL
$5.98 - $9.31 $1.49 Million - $2.33 Million
-249,778 Reduced 30.83%
560,492 $3.48 Million
Q1 2024

May 15, 2024
SELL
$6.7 - $12.0 $410,261 - $734,796
-61,233 Reduced 7.03%
810,270 $7.65 Million
Q4 2023

Feb 13, 2024
BUY
$3.18 - $6.86 $1.95 Million - $4.2 Million
612,276 Added 236.19%
871,503 $5.88 Million
Q3 2023

May 14, 2024
SELL
$3.25 - $6.08 $1.99 Million - $3.72 Million
-612,276 Reduced 70.26%
259,227 $1.15 Million
Q3 2023

Nov 14, 2023
SELL
$3.25 - $6.08 $417,641 - $781,310
-128,505 Reduced 33.14%
259,227 $1.15 Million
Q2 2023

May 14, 2024
BUY
$2.26 - $3.8 $203,221 - $341,699
89,921 Added 30.19%
387,732 $1.28 Million
Q2 2023

Aug 14, 2023
BUY
$2.26 - $3.8 $203,221 - $341,699
89,921 Added 30.19%
387,732 $1.28 Million
Q1 2023

May 14, 2024
SELL
$2.83 - $13.99 $49,856 - $246,461
-17,617 Reduced 5.59%
297,811 $848,000
Q1 2023

May 11, 2023
SELL
$2.83 - $13.99 $49,856 - $246,461
-17,617 Reduced 5.59%
297,811 $848,000
Q4 2022

May 14, 2024
SELL
$5.01 - $8.35 $146,803 - $244,671
-29,302 Reduced 8.5%
315,428 $2.3 Million
Q4 2022

Feb 13, 2023
SELL
$5.01 - $8.35 $146,803 - $244,671
-29,302 Reduced 8.5%
315,428 $2.3 Million
Q3 2022

May 14, 2024
BUY
$4.92 - $9.1 $297,291 - $549,867
60,425 Added 21.25%
344,730 $2.79 Million
Q3 2022

Nov 10, 2022
BUY
$4.92 - $9.1 $297,291 - $549,867
60,425 Added 21.25%
344,730 $0
Q2 2022

May 14, 2024
SELL
$4.2 - $24.0 $2.47 Million - $14.1 Million
-587,198 Reduced 67.38%
284,305 $1.39 Million
Q2 2022

Aug 15, 2022
BUY
$4.2 - $24.0 $195,984 - $1.12 Million
46,663 Added 19.64%
284,305 $1.39 Million
Q1 2022

May 16, 2022
BUY
$9.96 - $23.65 $1.52 Million - $3.61 Million
152,759 Added 179.96%
237,642 $5.62 Million
Q4 2021

Feb 14, 2022
BUY
$14.0 - $28.44 $313,334 - $636,515
22,381 Added 35.81%
84,883 $1.5 Million
Q3 2021

Nov 10, 2021
BUY
$7.28 - $30.97 $455,014 - $1.94 Million
62,502 New
62,502 $1.76 Million

Others Institutions Holding FULC

# of Institutions
130
Shares Held
51.6M
Call Options Held
1.04M
Put Options Held
32.6K
View Full List

About Fulcrum Therapeutics, Inc.

FULC Quotes by TradingView
  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $200M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email